Bernard Fox received SITC lifetime achievement award

Bernard Fox was presented with the prestigious Lifetime Achievement Award by the Society for Immunotherapy of Cancer in recognition of his exceptional contributions to the field of cancer immunotherapy.

Bernard A. Fox is a highly regarded figure in the field of cancer immunotherapy, serving as the Co-Founder, President, and CEO of UbiVac, a biotechnology company focused on developing cutting-edge cancer vaccines and immunotherapies. In addition to his leadership role at UbiVac, Dr. Fox is an Adjunct Professor in the Department of Molecular Microbiology and Immunology at the prestigious Knight Cancer Institute, where he collaborates with leading scientists and clinicians to advance the understanding and treatment of cancer through immunotherapy.

Dr. Fox’s expertise and contributions extend beyond academia and industry, as he also serves as a valued member of the Board of Directors for the Oregon Bioscience Association. In this capacity, he plays a key role in fostering innovation and supporting the growth of the bioscience sector in Oregon, helping to bridge the gap between research, business, and public health.

In recognition of his outstanding contributions to cancer research and translational cancer therapy, Dr. Fox was honored in 2012 with the Harder Family Endowed Chair for Cancer Research. This prestigious chair was awarded in acknowledgment of his pioneering work in the development of novel cancer therapies, particularly his efforts in translating laboratory discoveries into practical treatments for patients. Dr. Fox’s career is a testament to his commitment to advancing scientific knowledge and improving outcomes for cancer patients worldwide, and his work continues to have a profound impact on the field of cancer immunotherapy.

Bernard A. Fox leads the Laboratory of Molecular and Tumor Immunology at the Earle A. Chiles Research Institute, which is recognized as a Providence Center of Excellence for immuno-oncology and cellular therapy. In this role, Dr. Fox spearheads cutting-edge research focused on understanding and developing innovative immunotherapies for cancer. Additionally, he oversees the Biospecimen Repository, a core facility at the institute that plays a crucial role in collecting and preserving biological samples for research purposes, aiding in the development of new cancer treatments and therapies.

About Molecular and Tumor Immunology Lab

The Laboratory of Molecular and Tumor Immunology, under the leadership of Dr. Bernard A. Fox, conducts both preclinical and clinical research focused on advancing cancer immunotherapy. The lab is dedicated to developing new strategies to enhance the therapeutic potential of immunotherapies and translating these findings into clinical applications. By combining immunotherapies with other cancer treatments, the team has contributed to first-in-human clinical trials. Using a range of advanced technologies, including genomics, peptidomics, and multiplex immunofluorescence, the lab conducts in-depth analyses of the immune response to cancer in both animal models and human patients.

A key area of focus for Dr. Fox and his team is the study of non-canonical and non-mutated neoantigens and their contributions to the cancer peptidome. In collaboration with academia and the biotechnology and pharmaceutical industries, the lab is leading efforts to understand how these unique neoantigens can be targeted in immunotherapies. The lab also employs tissue-based immunoscore and immunoprofiling techniques to evaluate immune responses, providing valuable insights into the tumor microenvironment and guiding treatment strategies to improve patient outcomes.

Awards

Bernard A. Fox has received numerous awards, including the Team Science Award, Extraordinary Service to Society Award, and Bridge Award (2020), the Visionary/Legacy Award (2015), the Harder Family Endowed Chair for Cancer Research (2012), the Spirit of Emilie Mission Inspiration Award (2009), and several international honors such as the Visiting Professor Award and Guest Professor Award (2001-2002), along with the Science Recognition Award for New Investigators (1990).

About the SITC Lifetime Achievement Award

The SITC (Society for Immunotherapy of Cancer) Lifetime Achievement Award is presented to individuals who have made exceptional and sustained contributions to the field of cancer immunotherapy. This prestigious award recognizes outstanding leaders whose groundbreaking research, clinical innovations, and advocacy have significantly advanced the understanding and treatment of cancer through immunotherapy.

It honors those who have had a lasting impact on the field, demonstrated leadership and dedication, and contributed to the progress of immunotherapy as a transformative approach to cancer treatment. The award is intended to celebrate the recipient’s lifetime of achievement and commitment to improving the lives of cancer patients worldwide.

For more information, visit oncodaily.com.